M Jadersten

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
    Martin Jadersten
    Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden
    J Clin Oncol 26:3607-13. 2008
  2. ncbi Myelodysplastic syndromes: biology and treatment
    M Jadersten
    Division of Hematology and Center of Experimental Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    J Intern Med 265:307-28. 2009
  3. ncbi Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
    Martin Jadersten
    Karolinska Institutet, Department of Medicine, Center for Experimental Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 94:1762-6. 2009
  4. ncbi New clues to the molecular pathogenesis of myelodysplastic syndromes
    Martin Jadersten
    Center for Experimental Hematology, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    Exp Cell Res 316:1390-6. 2010
  5. ncbi Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome
    M Carlsten
    Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 24:1607-16. 2010

Detail Information

Publications5

  1. ncbi Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
    Martin Jadersten
    Karolinska Institutet, Department of Medicine, Division of Hematology, Stockholm, Sweden
    J Clin Oncol 26:3607-13. 2008
    ..To assess the effect of erythropoietin (EPO) plus granulocyte-colony stimulating factor (G-CSF) treatment on survival and leukemic transformation in myelodysplastic syndrome (MDS)...
  2. ncbi Myelodysplastic syndromes: biology and treatment
    M Jadersten
    Division of Hematology and Center of Experimental Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    J Intern Med 265:307-28. 2009
    ..We perform in depth analyses of two of the most widely used treatments, erythropoietin and lenalidomide, discussing mechanisms of action, reasons for treatment failure and influence on survival...
  3. ncbi Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
    Martin Jadersten
    Karolinska Institutet, Department of Medicine, Center for Experimental Hematology, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 94:1762-6. 2009
    ....
  4. ncbi New clues to the molecular pathogenesis of myelodysplastic syndromes
    Martin Jadersten
    Center for Experimental Hematology, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
    Exp Cell Res 316:1390-6. 2010
    ..An improved understanding of the pathophysiology of MDS may lead to the identification of suitable targets for future drug development...
  5. ncbi Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome
    M Carlsten
    Department of Medicine, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 24:1607-16. 2010
    ..Thus, given the emerging evidence for NK cell-mediated immune surveillance of neoplastic cells, we speculate that reduced expression of DNAM-1 on bone marrow NK cells may facilitate disease progression in patients with MDS...